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Abstract
Many industrial sectors, frompharmaceuticals to consumerproducts, are required toprovide data on their
products to demonstrate their efﬁcacy and that they are safe for patients, consumers and the environment.
This periodof testing typically requires theuse of animalmodels, the validity ofwhichhasbeen called into
questiondue to thehigh rates of attrition acrossmany industries. There is increasing recognitionof the
limitations of animalmodels anddemands for safety and efﬁcacy testingparadigmswhich embrace the
latest technological advances andknowledgeof humanbiology.This perspective article highlights the
potential for biofabrication approaches (encompassing bioprinting andbioassembly strategies) tomeet
these needs andprovides case studies from three different industry sectors to demonstrate the potential for
newmarkets in thebioprinting community.Wealsopresent a series of recommendations to create a
thriving bioprinting environment.One that operates at the forefront of science, technology and innovation
todeliver improveddecision-making tools for themore rapiddevelopment ofmedicines, agrichemicals,
chemicals and consumerproducts, andwhichmay reduceour relianceon animals.
Introduction
The development of pharmaceutical and non-pharma-
ceutical substances across thebioscience sectors (pharma-
ceuticals, chemicals, consumer product, cosmetic and
agribusiness) requires them to be tested to ensure they are
safe for patients, consumers and the environment. In
some sectors, this period of testing often relies on animal
models (primarily rodents). However, animal models are
not always accurate predictors of the effects of a new
substance in humans or the environment and can be a
cause of attrition [1–3]. In drug development, reducing
attritionbyevena small amount can lead tohugeﬁnancial
savings and increased business growth while importantly
ensuring that innovative medicines reach patients who
need them [4]. This has called intoquestion theutility and
validity of current development approaches across the
bioscience sectors, and demands for safety and efﬁcacy
testing paradigms to embrace the latest technological
advances andknowledgeofhumanbiology [5].
Bioprinting or biofabrication (which encompasses
both bioprinting and bioassembly strategies) offers a
potential technological solution [6]. There is increas-
ing interest from the life science community in the
application of this technology to create biomimetic tis-
sues which could be used to replace poorly predictive
animal models for better understanding of human
health and disease, and in the development of safer
and more efﬁcacious chemicals [7–11]. Recent advan-
ces in biofabrication has resulted in bioprinting strate-
gies for creating in vitro 3D tissue models (ﬁgure 1)
that have the potential to accurately recapitulate the
complex architecture, cellular heterogeneity and
interactions of tissues and organs in the human body
[12, 13]. However, as with any new technology, there
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the beneﬁts are realised and it is adopted more
broadly. 3D bioprinting and related biofabrication
methods is no different, but given the pace at which
the ﬁeld hasmoved, there have been few opportunities
for the community to come together with other dis-
ciplines and end users to explore novel areas where
bioprinting could have a positive impact. As has
recently been highlighted [14], this is an important
step in knowledge sharing to understand novel mar-
kets for new technologies, and the scientiﬁc, commer-
cial, societal and animal welfare beneﬁts that wider
application of these technologies brings. Here, we pro-
vide a ‘call to arms’ for the biofabrication community,
to facilitate the development and application of bio-
printing technologies for improved safety and efﬁcacy
testing. Importantly, we have identiﬁed and focused
on three key organ/tissue areas that require urgent
solutions for three industry sectors (i.e.: pharmaceu-
tical, consumer product and agrichemical industries),
demonstrating the potential for new markets in the
bioprinting community and new opportunities for
accelerating innovation to improve models and in
turn increase productivity across these industries.
We also provide a series of recommendations to cre-
ate a thriving global bioprinting environment. One that
operates at the forefront of science, technology and inno-
vation to deliver improved decision-making tools for the
more rapid development of medicines, agrichemicals,
chemicals and consumer products, and which may
reduceour relianceonanimals.
Case study 1—in vitromodels of liver structure and
function for assessment of hepatotoxicity and
carcinogenicity in plant protection product
development
The continuing growth in global population, together
with rising calorie consumption, has resulted in a
potentially unsustainable demand for food. It is the vision
of agribusinesses to bring greater food security in an
environmentally sustainable way to help meet this
demand for yield gain. As such, their product portfolios
include a broad range of plant protection products (PPPs;
e.g., herbicide, insecticide, or fungicide) which require
comprehensivemammalian toxicity evaluation, including
carcinogenicity studies, before they can be registered in
most regionsof theworld.
It is a requirement that all active substances be tes-
ted in at least two species (usually rat and mouse) for
their potential to act as carcinogens. The liver is a com-
mon target organ in agrochemical carcinogenicity
Figure 1Applicationof bioprinting technologies topotentially improvedrug andchemical developmentprocesses (* this doesnot apply to
personal care/cosmeticproducts). Currentdrug/chemical developmentprocesses relyona combinationof animal and in vitrodata to
support decisionmaking.The future applicationofpotentiallymorephysiologically relevantbioprinted in vitromodels duringpreclinical
development could go a substantialway to realising a futurewhere animal testing is no longerneeded in some instances. Summaryof the ‘3D
bioprinted in vitroHumanTissuesModels’whichcouldbemorewidely applied in current and futurepreclinical drug/chemical development
processes to reduce relianceonanimalmodels and improve translation tohumans. (a)Brain cortical tissue, reprinted from [35],Copyright
2015,withpermission fromElsevier, (b)pancreatic islets, reproduced from [36].© IOPPublishingLtd.All rights reserved, (c)3D lungmodel,
reprintedbypermission fromMacmillanPublishersLtd: ScientiﬁcReports [37], Copyright 2015, (d)3D tumourmodel, reproduced from
[38].© IOPPublishingLtd.All rights reserved, (e)3Dskinmodel [27, 39], Reproduced from [27].© IOPPublishingLtd.All rights reserved,
(f) cartilage tissue [40, 41], reproduced from [40].© IOPPublishingLtd.All rights reserved, (g)bone graft, reprintedbypermission from
MacmillanPublishers Ltd:NatureBiotechnology [42], Copyright 2016, (h) cardiac tissue [43, 44], reproduced from [43].© IOPPublishing
Ltd.All rights reserved, (i)microvascularature andvascularised thick tissue [45]Copyright (2016)NationalAcademyof Sciences, (j) liver
tissue, reproduced from [8].© IOPPublishingLtd.CCBY3.0, (k)kidney renal tissue, reproduced from [46]. CCBY4.0., (l)3Dvasculature,
from [47].©The authors, some rights reserved; exclusive licenseeAmericanAssociation for theAdvancementof Science.Distributedunder a
CreativeCommonsAttributionNonCommercial License 4.0 (CCBY-NC)http://creativecommons.org/licenses/by-nc/4.0/.
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studies. Hepatocellular hyperplasia is a common
injury response to chemical exposures in rodent toxi-
city studies and may result in unfavourable toxicity
proﬁles in long term toxicity studies. Current approa-
ches for examination of liver toxicity require samples
taken from repeat dose in vivo studies, but in a conven-
tional testing paradigm such studies are conducted
only after other in vivo toxicity studies have been com-
pleted. Earlier identiﬁcation of unfavourable areas of
chemistry may reduce the number of animal studies
conducted with compounds which are ultimately
determined to be unsafe or unregisterable.
However, the utility of these studies has been called
into question. Carcinogenicity studies run in rats are not
necessarily predictive of the result of similar studies run in
mice [15], and liver tumours in rodent models are not
conclusive evidence that a compoundwill exert a carcino-
genic effect in humans (as a result of rodent-speciﬁc
tumorigenic mechanisms). To examine the human rele-
vance of tumours observed in rodent carcinogenicity stu-
dies, in vitro and in vivomodels are used to establish the
adverseoutcomepathway (AOP)underlying the observed
effects [16]. Once established in rodents, the sequence of
causative key events in theAOPcanbe interrogated across
species to examine the relevance of rodent toxicities to
humans. Currently the establishment and cross species
interrogation of key events inAOPs is a complex, iterative
undertaking requiring anumberof animal studies.
Whilst current in vitro models are able to provide
insights into the AOPs of liver toxicity, existing models
do not accurately reproduce the architecture of liver tis-
sue and often do not include the full range of cell types
present in vivo (including hepatocytes, cholangiocytes,
Kupffer cells, liver endothelial cells, and hepatic stellate
cells). As a result, existing in vitro liver models are gen-
erally not suitable for histopathological analysis, limiting
the potential for validation of thesemodels against exist-
ing in vivo toxicity databases and their ability to predict
the outcomeof in vivo studies. Furthermore, the absence
of architecture and use of limited cell types in existing
models prevents accurate mimicry of tissue micro-
environments, potentially reducingmodel predictivity.
Bioprintedorganmodels and tissues couldpotentially
be used to both establish AOPs and as a tool to facilitate
evaluation of the relevance of rodent tumours to humans,
increasing the conﬁdence in safety assessments and redu-
cing the reliance on animalmodels. This could help guide
early stage agrochemical research projects away from
toxic areas of chemistry through early detectionof hepatic
toxicants and structure-activity relationship building.
Rapid advances are being made in this area [17–19], but
there still remain a number of critical considerations
which need to be accounted for during future model
development to maximise the potential of these tools in
the contextof safety assessmentofPPPs—see table 1.
To be useful models for mode of action (MOA)
investigation and as a predictive tool for compound
development, the response of bioprinted constructs to
hepatotoxins should be demonstrated to mirror the
physiological, histological and biochemical responses
observed in humans and rodents. The properties that a
bioprinted livermodel should exhibit in order to func-
tion as a predictive model are likely to require further
investigation, however factors including metabolic
capability (e.g. expression and activity of phase I and II
enzymes), gene and protein expression (particularly of
key nuclear receptors including the peroxisome pro-
liferator activation receptors, constitutive androstane
receptor, pregnane X receptor, retinoid X receptor,
aryl hydrocarbon receptor, farnesoid X receptor, and
glucocorticoid receptor) and cellular structure (open
questions include the necessity of Kupffer cells in
modulating responses to hepatotoxicants) are likely to
prove important inmodel development.
Details regarding the manufacture of bioprinted
constructs, such as whether constructs are created in
the presence or absence of a scaffold are unlikely to be
a serious concern for industry, as the primary concern
for these models will be around predictivity and vali-
dation rather than method of manufacture. How
amenable the tissue is to histology is also an important
consideration in being able to back translate responses
to existing liver toxicity data and provide a degree of
conﬁdence in the ability of the model to predict
human responses. Whilst precursor events are com-
monly observed in sub-acute and sub-chronic toxicity
studies, most liver carcinogenicity observed with agro-
chemicals is the result of chronic exposure. As such the
longer term stability of the model (up to 28 days) in
culture is important to provide sufﬁcient time course
data to be able to predict chronic effects and support
the development of appropriate AOPs.
Case study 2—human-relevantmodels of
respiratory disease in pharmaceutical drug
development
The pharmaceutical industry is facing considerable
challenges in the development of new safe and efﬁca-
cious innovative medicines. Productivity has declined
steadily over the last two decades, despite the investment
in drug development doubling every nine years over the
last 60 years. Only 10% of drug candidates entering the
clinic achieve US Food and Drug Administration
approval [20] and, according to some studies, it now
costs approximately $2.6 billion to develop a drug [21].
A number of factors contribute to the high attrition rate
and costs in drug development, including higher
regulatory hurdles for safety and efﬁcacy and commer-
cial considerations including reimbursement strategies
as well as strategic portfolio decisions driving project
termination. But a substantial proportion of this failure
can be attributed to the lack of safety or efﬁcacy,
suggesting the preclinical models used to assess these
poorly translate to the clinic [22].
Respiratory disease remains an area of consider-
able unmet medical need with signiﬁcant barriers to
new drug development [23]. Many of the new
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respiratory drugs that have failed in the clinic have
performed well in preclinical animal models, suggest-
ing more predictive models and tools based on the lat-
est technologies, including bioprinting, are required.
But what these models should look like will clearly
depend on the question being asked, and what part-
icular respiratory disease you are studying. A ‘one size
ﬁts all’model will not work, and therefore engagement
and collaboration between the bioprinting commu-
nity and end-users early in model development is
essential for delivering bespokemodels with utility.
Diseases such as asthma and chronic obstructive pul-
monary disease are complex, heterogeneous diseaseswith
diverse aetiologies. Not one singlemodel is likely to repli-
cate all of the necessary features to recreate these diseases
in vitro, but there are some common features that are
essential starting points. These include being able to
model airway hypersensitivity and inﬂammatory cell
recruitment. For example, bioprinting the bronchiolar
epithelium should include not only the simple ciliated
columnar cells but also secretory Clara cells, as well as
neuroendocrine cells. Alveolar units should comprise
Type I cells and Type II cells while pulmonary vascular
tissues should include endothelial cells fromdifferent vas-
cular structures, smooth muscle cells, and adventitial
ﬁbroblasts [24]. Importantly, any bioprinted lung
mimetic should incorporate cells from the innate
immune system or even adaptive immune systems if
studying a particular pathogen to aid our understanding
of the immune processes which drive respiratory disease.
Given the chronicity of respiratory disease, it is important
that bioprinted material can be used over a prolonged
period of time and therefore demonstrate viability of
weeks and preferably months, rather than days. As our
ability to stratify patient phenotypes improves, we also
requiremodels that represent the heterogeneity of patient
subpopulations. Such an approach is also likely to require
mathematical modelling to determine the appropriate
numberof variants to create and study.
Understanding the basic anatomical and cellular
components for bioprinting lung models suitable for
drug discovery is the ﬁrst step towards creating useful
models for improved efﬁcacy and safety testing with-
out animals. Working collaboratively with the end-
users will ensure that material is printed and models
are built that address the gaps evident with current
models. Related to this, by working in a partnership
the bioengineering community will understand how
and why the models are used and at what point in the
drug discovery/development pipeline they will be
deployed. Of particular value is the bioprinting of cells
for use within phenotypic screens that elucidate new
targets or drive a greater understanding of biological
targets early in preclinical drug development. This has
the beneﬁt of enabling companies to identify early
those compounds destined to fail and remove them
from development before the more expensive animal
testing stages—fail early; fail cheap is the commonly
used mantra. For these early screens where thousands
of potential therapeutics will be assessed to identify if
they can alter the phenotype of a cell or tissue in a
desired manner, the models need to be fairly simple to
meet the demands for high-throughput and high-con-
tent systems and importantly cost-effective and highly
reproducible. However, if bioprinted material is
employed in the latter stages of discovery, for example
prior to candidate drug nomination, a lower through-
put, more complex system is preferred. In this sce-
nario, the model should try to emulate physiological
or pathophysiological responses that are not detect-
able in animal models or other complex in vitromodel
systems.
Case study 3—bettermodels to assess the beneﬁts
and safety risks of consumer products on skin
The consumer goods industry spans a number of
different product types, including foods, drinks,
homecare and personal care products. Since 2013,
legislation in the European Union has banned the
marketing of cosmetics and personal care products
that contain ingredients that have been tested on
animals. For some toxicity endpoints (e.g. skin corro-
sion, eye irritation and androgen receptor activity),
Organisation of Economic Cooperation and Develop-
ment test guidelines exist to allow data generation
without using animals. However, for other important
toxicity endpoints, no guidelines currently exist. The
marketing ban has the potential to stiﬂe innovation in
the sector and so there has been a concerted effort
Table 1.Comparison of existing in vivo and in vitro technologies for studying liver injury.
Property Achievable in vivo Achievable in vitro
Mimicry of normal human livermetabolic
function
Yes, although species differences in
metabolism can occur
Yes, but results are sometimes of unclear
relevance to in vivo
Assessment ofmolecular endpoints (protein
induction,mRNA)
Yes Yes, but results are sometimes of unclear
relevance to in vivo
Detection of cell proliferation Yes Yes
Suitable for histopathological examination Yes No
Assessment of organweight changes Yes No
High temporal resolutionmeasurements
(<1 day)
Possible but not commonoutsidemeta-
bolism studies
Yes
Replicate number Limited bywelfare concerns Limited by practical concerns
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towards the development and application of new
in vitro approaches by the personal care products
industry. Bringing greater focus on human relevant,
in vitro MOA safety (and efﬁcacy) assessment and
embracing Safety Science in the 21st Century frame-
work approaches [25, 26].
The majority of homecare and personal care pro-
ducts interact with the skin either intentionally or as a
consequence of use in other capacities, and so asses-
sing the possible effects of these chemicals at both the
skin surface and underlying structures is an essential
part of consumer product development. In vitro cell
culture of human cells plays an important role in both
the identiﬁcation of new targets and leads and in assur-
ing their safety. Numerous 2D and 3D model systems
exist for this purpose, but their utility can sometimes
be limited because of their (i) cellular composition
(primarily keratinocytes and ﬁbroblasts), (ii) lack of
appendages and other macrostructures (e.g. hair folli-
cles, sebaceous glands, vascularisation) and (iii) inabil-
ity to represent other cell types in the skin (e.g.
immune cells, adipocytes, dendritic cells, melanocytes
etc). In this context, current 3D systems have only lim-
ited value in enabling the identiﬁcation of new targets
(e.g. in a hair biology/skin ageing context where the
presence of macrostructures and vascularisation are
key determinants of in vitro to in vivo functional
equivalence); neither do they represent sufﬁcient
human biology to advance our mechanistic under-
standing of adverse events (e.g. skin sensitisation,
where immune function is often poorly represented in
the availablemodel systems).
Bioprinting offers the ability to automatically fab-
ricate robust and reproducible 3D skin models with
improved human relevant functionality and which
possess critical attributes of the target tissues they
represent [27, 28]. These tissues can be conﬁgured to
mimic the cell density of the target tissue and to be
composed solely of the appropriate cells and extra-
cellular matrix they produce. Spatially deﬁned deposi-
tion of cell types also enables the design and
fabrication of tissues that recapitulate key archi-
tectural features of the target tissue in vivo. This spatial
patterning and cell alignment is crucial to the normal
functioning of most tissues, enabling cell–cell com-
munication to be more effectively emulated. More
highly complex skin models containing blood vessels
and nerve ﬁbres are potentially feasible, allowing for
questions of safety and efﬁcacy to be answered in a
more in vivo-like context—see box 1.
It is unlikely that it will be possible to develop a
single model that is capable of representing the
entirety of human relevant biology, and that bespoke
assays may be required to address, for example, effects
at the level of the hair follicle [29], or effects exploring
aging biomarkers, or immune responses in the skin. It
is clear that certain solutions/models are further off
than others in terms of their development and applica-
tion. Recapitulating functional structures in the skin
(e.g. sebaceous glands and hair follicles) is on a longer
term horizon than say the introduction of immune
competent cells into models, although this too is no
trivial endeavour. Maintenance of immune cells in
skin models is a key challenge as they are often short-
lived and are ‘recruited’ to the site of function.
Being able to measure the exposure of chemicals
via the dermal route is very important in any skin
model. Current approaches rely on the use of ex vivo
skin samples which lack functional vasculature, and so
penetration is measured as a function of transit
through the skin. Building in more human relevant
functionality, future bioprinted skin models should
incorporate tissue printing around pseudo-blood ves-
sels to supportmore relevant in vivo-like exposure stu-
dies. The availability and access to ex vivo skin is often
limited, therefore future bioprinting of 3D skin sam-
ples could potentially address this need and bring
greater consistency/standardisation concerning the
tissue supplied. Other safety endpoints of importance
that should be considered in the development of bio-
printed skin models include standard measures of
cytotoxicity, genotoxicity and allergy. Immunotox-
icology is of particular interest because of the deﬁ-
ciencies acknowledged in currently available 3D
models regarding the absence of immune function
and critical cell types (for example dendritic cells, mast
cells, T-cells). 3D bioprinted models able to incorpo-
rate and retain these cell types within the tissue con-
struct would represent a signiﬁcant step forward in
consumer product development.
Conclusions and recommendations
There are clear opportunities for the application of
bioprinting approaches to support pharmaceutical
and non-pharmaceutical chemical development, and
there is good appetite from both the bioprinting and
life science communities to realise this [14]. Bioprint-
ing potentially offers key advantages in the develop-
ment of more functionally relevant/predictive models
for basic and applied research, when compared to
more traditional 3D cell culture approaches which do
not go beyond simple prototissue models (see table 2
and [12, 13]). Although the case studies presented here
originated from different industry sectors, the devel-
opment of well-characterised, reproducible, afford-
able, human relevant bioprintedmodels of any organ/
tissue would be welcomed across the life science
sectors.
However, the critical components of in vivo biology
described in the case studies are not likely to be well
known by the engineers developing the bioprinting
technology capable of creating these models. Therefore,
amore concerted effort is needed to support these com-
munities in coming together at the start of model devel-
opment to save time and resources while maximising
the expertise available in understanding end-user
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requirements and technological capabilities. Many hur-
dles exist to this (see table 2), and some of these may be
more easily overcome than others, but the potential
beneﬁts to the science base, chemical development and
the 3Rs aremany.
Recommendations to address these hurdles and
maximise the opportunities are described below.
These focus on better cross-sector and -discipline
engagement in (i) deﬁning the problems that can be
solved together; and (ii) developing strategies to sup-
port acceptance of bioprinted models by senior
decision makers. A key thread linking these themes is
the need to form longer-term partnerships between
large companies (e.g. pharmaceutical, consumer pro-
ducts, etc), SMEs, and universities; and it is important
that funders and regulators also play their part in sup-
porting this.
1.Deﬁne a clear problem statement
The life science community needs to be more
coordinated to work in partnership to deﬁne
focussed, translatable and tractable problems that
can be solved using bioprinted models. Central to
this is the need to provide a forum for potential
industry end-users to work collaboratively in a pre-
competitive manner to deﬁne and prioritise which
disease-speciﬁc bioprinted models they would like
to have access to and the minimum starting criteria
(structure and function) for those models to be
useful. Demonstrating successful examples of the
application of viable bioprinted models to highlight
scientiﬁc and commercial feasibility and industrial
‘pull-through’ will help to encourage the wider
engagement of both the academic and industrial
sectors. Expanding collaborative programmes for
challenge-led innovation and strategic funding (e.g.
CRACKIT [30])will alsohelp toengageand support
technology developers and multidisciplinary teams
in developing bioprinting approaches for solving
biology challenges.
2. Supporting validation and senior decision maker
acceptance through collaboration
Validating new models is an important and
ongoing phase of model development, during
which physiological baseline data and responses
to compounds are assessed and compared with
clinical outcomes. Establishing an approach for
Table 2.The opportunities for, and hurdles to, wider adoption of bioprintedmodels for efﬁcacy and safety testing in drug and chemical
developmenta.
Opportunities Hurdles
The potential for improved reproducibility of tissue fabrication—
especially important when being used to assess safety/efﬁcacy of
compounds reliably over time
There is a current lack of validation of existingmodels to support
wider uptake and acceptance by decisionmakers and regulatory
authorities
The ability to print usinghumanmaterial [8] and incorporate greater
structural complexity, e.g. incorporating sweat glands, hair folli-
cles andother appendages in skinmodels, and close proximity
bioprinting of immune and structural cells in lungmodels
Current bioprinting equipment ismostly bespoke, encouraging a
wide diversity in devices and limiting their use in awide range of
applicability domains
The potentially improved functionality due to incorporating
greater structural complexity
The perceived reluctance of regulatory authorities to accept data
derived in non-animalmodels to support clinical trial applications
The potentiallymore predictive responses generated inmore
in vivo-like, human tissuemodels
A lack of opportunities for cross-sector and –discipline communica-
tion to understand user needs and bioprinting capabilities
The speed, relative ease and reduced cost at which tissue can be
fabricated
A lack of standardisation ofmodels and the criteria for assessing
model performance
The potential for personalised bioprinting as a route to enable and
accelerate the realisation of personalisedmedicine
Inertia and a reluctance to embrace change andmove away from cur-
rently used in vitro and in vivomodels
a These represent the consensus views of the biofabrication and industry community as discussed at [14].
Box 1. Five key areas where bioprinted skinmodels will be especially
beneﬁcial.
Improved speed and accuracy for identiﬁcation of lead actives.
Improved consistency and biological relevance of thesemodels
and the capacity for high throughput productionmay deliver
superior screening technology, leading tomore effective identiﬁ-
cation and validation of leadmolecules.
More predictive tissuemodels for investigative research and target iden-
tiﬁcation.Buildingmulti-cellularmodels,more closely predictive
of the in vivo tissue, will allow tissue physiology and function to be
investigatedmore effectively, leading to better identiﬁcation of
lead targets.
More biologically relevantmodels for assessing effects on pathways.
Assessing the safety of new leadmolecules using a pathways-based
approachwill beneﬁt from an increased availability of human-
relevant biologicalmodels to use, particularly in pathways/
organs that are poorly covered by currently availablemodels.
Potential replacement for limited human tissue supply.The incorpora-
tion of iPS cells into thesemodels will provide an alternative
source of cells for incorporation into the 3Dmodels. An inex-
haustible supply of identical cells will be available for repeat sys-
temsmodelling and higher throughput testing.
Better prediction of clinical outcomes.The increased relevance of these
models to the in vivo tissue has the potential to decrease lead time
and deliver a higher proportion of successful clinical outcomes.
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technology developers and end-users (cross-com-
pany and -sector) to work collaboratively on
deﬁning a compound library (including asso-
ciated in vivo data and mechanistic/pharmacol-
ogy information where possible) for testing
bioprintedmodels for efﬁcacy and safety testing is
essential in supporting this validation process.
Expediting the often lengthy validation process
requires a tiered approach that would ﬁrstly
demonstrate industry’s willingness to use, and
acceptance of, bioprinted models in safety and
efﬁcacy decisionmaking. Regulatory acceptability
of a bioprinted model for decision making is
crucial to enable successful registration of pro-
ducts and as conﬁdence grows in this sector,
acceptance by the regulatory agencies would likely
follow. Establishing an approach to support
demonstrators within institutions or companies
to generate interest and provide access for trial use
to familiarise potential users would engender
greater conﬁdence in the utility of bioprinted
models and encourage potential uptake.
Regulatory acceptance is an important factor
when considering whether or not to adopt a novel
technology for decision making. Therefore it is
important to support wider use of existing
mechanisms for technology developers and end-
users to engagewith regulators onmodel develop-
ment and to receive feedback on the potential for
safety data generated in bioprinted models to be
accepted by regulatory agencies. Both the UK
Medicines and Healthcare products Regulatory
Agency (MHRA; [31]) and European Medicines
Agency (EMA; [32]) have safe harbour
approaches to facilitate this. However, as a global
industry, without engaging additional regulatory
agencies in embracing similar approaches for
greater dialogue with technology developers and
end-users onmodel development and application
it may be difﬁcult to convince some companies
and sectors to adopt novel bioprintingmodels.
3. Supporting cross-sector and -discipline collabora-
tion
There should be greater opportunities to enable
closer working relationships between scientists
with the diverse skill sets necessary for the
successful development and application of bio-
printed models, for example, engineers, biolo-
gists, chemists, materials scientists and industry
end-users. Speciﬁc forums to facilitate this will
enable better understanding of end-user model
requirements and bioprinting capabilities and
reduce the potentially unrealistic expectations of
what the technology can deliver.
Funding will always be a key driver for this
collaborative approach to research and develop-
ment, so continued and increased collaboration
between funders for example in the UK the
NC3Rs, Innovate UK, and the Research Councils
to nurture long-term partnerships between lead-
ing scientists, centres of excellence, and industry,
should be encouraged. As should more multi-
agency research funding calls recognising the
multidisciplinary nature of bioprinting develop-
ment and application.
4.Adding value to in vitromodels
Applying bioprinting approaches in the creation
of more human-like cell culture models, for
example by incorporating immune cells to inves-
tigate modulation of the immune response; and
hair follicles in skin models, relies on provision of
opportunities for focused cross-sector and -dis-
cipline collaboration. Going beyond this, it is
necessary to also support interdisciplinary colla-
boration to maximise the utility of other technol-
ogies through the incorporation of more human
relevant bioprinted models. For example, micro-
ﬂuidic organ-on-chip platforms have become an
important tool to understand the role of cellular
interactions and the impact of potential therapeu-
tics to model and treat disease [33]. Because of its
versatility, 3D bioprinting has emerged as a
leading tool for fabricating in vitro biomimetic
devices that capture some of the more complex
functions of the human body [34]. Conversely,
incorporating other approaches such as mathe-
matical and in silicomodelling within bioprinting
strategies can help inform and speed up this
biomimetic model development. Finally, to
achieve a step-change in scale-up and manufac-
ture of bioprinting-based technologies and mod-
els, there must be increased focused activity to
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